Author/Authors :
Fahmy, Azza Department of Immunology and Drug Evaluation, Giza, Egypt, UAE , Abuelenain, Gehan Department of Immunology and Drug Evaluation, Giza, Egypt, UAE , Abdou, Amr Department of Microbiology and Immunology, NRC, Giza, Egypt , Elhakeem, Mohamed Water Resources and Environmental Engineering, ADU, Abu Dhabi, UAE
Abstract :
To investigate the prophylactic and therapeutic potentiality of Egyptian probiotic Lactobacillus reuteri in the
cryptosporidiosis model (hereafter home-isolated probiotic). As per the health conditions of the experimental mice,
they were deployed into two main batches: immunocompetent and immunocompromised. Each batch comprised
three protocols as per the types of the treatment (home-isolated-, commercial probiotics, and Nitazoxanide). A dose
of 108
colony-forming unit (cfu) Lactobacillus reuteri isolated from the domestic camels and the commercial strain were
administered orally on daily basis for 10 days. Then, mice were infected with approximately 1 x 104 inoculums of Cryptosporidium cysts with continuous administration of probiotics till the end of the experiment (day 20). The regression
decay models were utilized to predict the recovery rate of the experimental mice at days different from the tested ones
using the data collected from the Nitazoxanide-different time-scheduled protocol. The response to the treatment by
probiotics in the immunocompromised mice is less than that of the immunocompetent mice. Positive outcome results
are in favor of the home-isolated probiotic treatment. On the contrary, Nitazoxanide is the treatment with the highest
number of cysts recovered from the experimental mice. In a nutshell, the results demonstrate that the home-isolated
probiotic is efficient in decolonizing the Cryptosporidium spp. cysts and ameliorating the pathogenicity of the disease.
Besides, this research study is shedding the light on the importance of isolating and utilizing a country/region-based
Lactobacillus reuteri probiotic for high-efficiency treatment of cryptosporidiosis in immunodeficient cases.
Keywords :
Cryptosporidiosis , Nitazoxanide , Probiotic , Drug discovery